Beata Miklaszewicz & Dariusz Dabrowski Cardiamed Sp. j.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Beata Miklaszewicz & Dariusz Dabrowski Cardiamed Sp. j. in Legnica, the cardiovascular research portfolio focuses on major conditions such as atrial fibrillation, heart failure, and atherosclerotic cardiovascular disease. These studies are designed to evaluate new approaches that may help reduce serious events like stroke, worsening heart failure, and other complications.
- Testing therapies for atrial fibrillation to lower the risk of stroke and systemic embolism
- Evaluating treatments for heart failure to reduce cardiovascular death and urgent hospital visits
- Studying new options for atherosclerotic cardiovascular disease to prevent major adverse cardiovascular events
- Assessing cardiovascular outcomes in people with overweight or obesity alongside heart disease
Overall, the site is contributing to research that aims to improve prevention, symptom control, and long-term outcomes in high-risk cardiac populations.
Nutritional and Metabolic Diseases
The site also supports studies in nutritional and metabolic disease, with a strong emphasis on overweight, obesity, type 1 diabetes, and type 2 diabetes. This research is centered on improving blood sugar control, supporting weight reduction, and exploring therapies that may help patients manage chronic metabolic conditions more effectively.
- Investigating treatments for type 1 diabetes to improve glycaemic control
- Comparing approaches for type 2 diabetes when standard treatment is not enough
- Studying weight-loss therapies for people with overweight or obesity
- Exploring combined strategies for patients with obesity and diabetes
These trials reflect a broader effort to test new therapies that may better support metabolic health and reduce the burden of long-term disease.
Respiratory Tract Diseases
Research in respiratory disease at this clinic includes studies in chronic obstructive pulmonary disease, with attention to reducing flare-ups and improving disease management. The work is aimed at evaluating whether new treatment strategies can help patients experience fewer exacerbations and better day-to-day respiratory stability.
- Studying therapies for COPD to reduce the frequency of exacerbations
- Assessing treatment effectiveness in people with chronic lung disease and related health risks
- Exploring whether existing medicines may offer added benefit in respiratory care
This area adds an important pulmonary dimension to the site’s clinical trial activity, complementing its cardiovascular and metabolic research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Beata Miklaszewicz & Dariusz Dabrowski Cardiamed Sp. j.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 2 | Unknown | 2024-10-18 | 2025-08-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.